ArticleClinical case reports2026
Cangrelor Bridge for Repeat Cesarean After Third Trimester Percutaneous Coronary Intervention for Total Occlusion NSTEMI.
Article in Clinical case reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acute coronary syndrome is an uncommon but potentially life-threatening complication in pregnancy, and dual antiplatelet therapy presents challenges in patients requiring cesarean delivery. We present a 39 year-old woman who presented at 29 weeks gestation with a non-ST segment myocardial infarction (NSTEMI). Urgent coronary angiogram revealed 100% occlusion of the left anterior descending coronary artery. She underwent percutaneous coronary intervention (PCI) with one drug-eluting stent and was initiated on dual antiplatelet therapy. Due to prior classical cesarean delivery, she required repeat cesarean less than 3 months from PCI. Cangrelor was used as bridging therapy prior to cesarean delivery at 37 weeks gestation to balance the thrombotic and bleeding risks. This case underscores the importance of recognizing total coronary occlusion in NSTEMI presentations and is, to our knowledge, the first reported use of intravenous cangrelor as perioperative bridging therapy for cesarean delivery in a pregnant patient with recent PCI for acute coronary syndrome.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.